Maurer Till
Department of Structural Biology, Genentech Inc., South San Francisco, California, USA.
Methods Enzymol. 2011;493:469-85. doi: 10.1016/B978-0-12-381274-2.00018-2.
The application of NMR in fragment-based lead discovery (FBLD) has quickly developed from a sensitive method for the identification of low-affinity binders to an important tool in the hit-to-lead process. NMR can play a constructive role in the process from identifying those fragments with the best potential toward a biochemically active compound to developing them into molecules with high affinity and selectivity to a given target protein. NMR hit-to-lead involves revising the lead identification process at the beginning of a fragment-based drug discovery project, the primary screen, and also looking toward protein-detected NMR methods in advancing compounds from fragment hit into and through fragment hit-to-lead. With the development of higher sensitivity cold NMR probes, ligand-based NMR methods can be successfully applied to a majority of projects found in a pharmaceutical pipeline. Having matured from the original concepts such as SAR by NMR (Shuker, S. B., Hajduk, P. J., Meadows, R. P., Fesik, S. W. (1996) Discovering high-affinity ligands for proteins: SAR by NMR. Science274 (5292), 1531-1534.), projects that base their lead matter on fragment hits are close to or already in the clinic (Woodhead, A. J., Angove, H., Carr, M. G., Chessari, G., Congreve, M., Coyle, J. E., Cosme, J., Graham, B., Day, P. J., Downham, R., Fazal, L., Feltell, R., et al. (2010) discovery of (2,4-dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl]methanone (AT13387), a novel inhibitor of the molecular chaperone Hsp90 by fragment based drug design. J. Med. Chem.53, 5956-5969, Chessari, G., and Woodhead, A. J. (2009). From fragment to clinical candidate: A historical perspective. Drug Discov. Today14 (13-14), 668-675.). Generating new ideas toward new binding modes and mechanisms of action as well as new intellectual property will be the standard by which the success of FBLD will need to be measured. A strategy outlining the various steps involved in NMR hit-to-lead is provided. By means of a specific example, the workflow is described to guide the reader through the experimental setup.
核磁共振(NMR)在基于片段的先导化合物发现(FBLD)中的应用已迅速从一种用于鉴定低亲和力结合物的灵敏方法发展成为从命中物到先导化合物过程中的重要工具。在从识别最具潜力的片段到将其开发成对给定靶蛋白具有高亲和力和选择性的分子的过程中,NMR可以发挥建设性作用。NMR从命中物到先导化合物的过程涉及在基于片段的药物发现项目开始时即初级筛选阶段修正先导化合物的识别过程,并且在将化合物从片段命中物推进到片段命中物到先导化合物的过程中还要关注蛋白质检测的NMR方法。随着更高灵敏度的冷NMR探头的发展,基于配体的NMR方法能够成功应用于药物研发流程中的大多数项目。基于NMR的构效关系(SAR)等原始概念已发展成熟(舒克,S.B.,哈杜克,P.J.,梅多斯,R.P.,费西克,S.W.(1996年)通过NMR发现蛋白质的高亲和力配体:基于NMR的构效关系。《科学》274(5292),1531 - 1534),基于片段命中物的先导化合物项目已接近或已进入临床阶段(伍德黑德,A.J.,安戈夫,H.,卡尔,M.G.,切萨里,G.,康雷夫,M.,科伊尔,J.E.,科斯梅,J.,格雷厄姆,B.,戴,P.J.,唐纳姆·R.,法扎尔,L.,费特尔,R.等(2010年)通过基于片段的药物设计发现分子伴侣Hsp90的新型抑制剂(2,4 - 二羟基 - 5 - 异丙基苯基) - [5 - (4 - 甲基哌嗪 - 1 - 基甲基) - 1,3 - 二氢异吲哚 - 2 - 基]甲酮(AT13387)。《药物化学杂志》53,5956 - 5969,切萨里,G.,和伍德黑德,A.J.(2009年)。从片段到临床候选物:历史视角。《今日药物发现》14(13 - 14),668 - 675)。产生关于新的结合模式、作用机制以及新的知识产权的新想法将成为衡量FBLD成功与否的标准。本文提供了一个概述NMR从命中物到先导化合物所涉及的各个步骤的策略。通过一个具体例子,描述了工作流程以引导读者了解实验设置。